Skip to Content

Coloplast A/S ADR CLPBY

Morningstar Rating
$13.21 −0.23 (1.71%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Coloplast Earnings: Underlying Demand Remains Strong, but Medicare Fraudsters Could Hurt U.S. Growth

Coloplast posted fiscal first-quarter results that featured robust organic revenue growth as well as ongoing margin pressure. On the whole, quarterly results largely met our expectations, and our minor model adjustments weren’t enough to materially shift our fair value estimate. Favorable market reaction to new intermittent catheter Luja as well as Kerecis fish skin underscores Coloplast’s intangible assets that support its wide economic moat. Though the shares have risen over the last three months, we think Coloplast remains modestly undervalued.

Price vs Fair Value

CLPBY is trading at a 6% discount.
Price
$13.21
Fair Value
$49.30
Uncertainty
Medium
1-Star Price
$23.14
5-Star Price
$8.24
Economic Moat
Tstm
Capital Allocation
Yxhxcykzfr

Bulls Say, Bears Say

Bulls

Because of aging populations in developed countries, the incidence of colorectal disease is growing. Independent of age, the incidence of inflammatory bowel disease is also on the rise.

Bears

Now that Coloplast has already shifted most of its manufacturing to low-cost geographies, gains in gross margin may not be so easy to achieve.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CLPBY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$13.44
Day Range
$13.1213.22
52-Week Range
$9.9014.77
Bid/Ask
$12.62 / $13.19
Market Cap
$29.70 Bil
Volume/Avg
39,363 / 112,351

Key Statistics

Price/Earnings (Normalized)
41.22
Price/Sales
7.90
Dividend Yield (Trailing)
2.30%
Dividend Yield (Forward)
2.30%
Total Yield
2.30%

Company Profile

Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Large Growth
Total Number of Employees
15,751

Competitors

Valuation

Metric
CLPBY
SNN
BSX
Price/Earnings (Normalized)
41.2214.9332.68
Price/Book Value
13.232.215.09
Price/Sales
7.902.086.88
Price/Cash Flow
32.7612.2829.94
Price/Earnings
CLPBY
SNN
BSX

Financial Strength

Metric
CLPBY
SNN
BSX
Quick Ratio
0.350.830.63
Current Ratio
0.532.191.32
Interest Coverage
9.202.818.41
Quick Ratio
CLPBY
SNN
BSX

Profitability

Metric
CLPBY
SNN
BSX
Return on Assets (Normalized)
12.14%6.86%8.92%
Return on Equity (Normalized)
47.39%12.92%16.33%
Return on Invested Capital (Normalized)
16.96%9.28%11.43%
Return on Assets
CLPBY
SNN
BSX
See how this stock stacks up to its competitors with Morningstar Investor

Medical Instruments & Supplies Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ISRG
Intuitive Surgical IncCvdh$136.2 Bil
BDX
Becton Dickinson & CoKfqngfh$69.1 Bil
ALC
Alcon IncHcbjjs$41.8 Bil
WST
West Pharmaceutical Services IncXwzk$26.2 Bil
RMD
ResMed IncXkmlb$25.6 Bil
BAX
Baxter International IncYrlqz$21.1 Bil
COO
The Cooper Companies IncWkwwn$18.8 Bil
HOLX
Hologic IncYjqhyxv$17.4 Bil
TFX
Teleflex IncWtfqj$10.6 Bil

Sponsor Center